Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Post by need2stockupon May 05, 2011 8:15pm
357 Views
Post# 18537674

We are the Covidien in the Zars deal

We are the Covidien in the Zars dealYes Zars started out in 2003 with only the license to manufacture and market S-Caine for Ferndale Lab. Products. Now Nuvo Covidien has moved in. Me thinks Dannyboy has thoughts of grandeur.
December 10, 2003 contactus@ferndalelabs.com
Ferndale, Michigan-December 9, 2003-Ferndale Laboratories Inc, has signed a license agreement with ZARS, Inc., to manufacture and market the S-Caine Patch product which is intended to be used to numb the skin before painful medical procedures, such as, vascular access, minor dermatological procedures, vaccinations etc. The S-Caine Patch is the subject of a pending NDA submitted to the FDA in March of 2003.
Michael Burns, Ph.D., President and COO of Ferndale stated, “We are delighted to be entering into this partnership with the highly creative team at ZARS. The execution of this licensing agreement represents a major milestone for both our companies. The S-Caine patch is a new and highly innovative product that will satisfy a substantially unmet need in the management of acute pain associated with needle-sticks or related procedures and will further solidify Ferndale’s leading position in the topical anesthetic market.”
Larry Rigby, President and CEO of ZARS stated, “We are extremely pleased to be partnered with Ferndale Laboratories. Their reputation in dermatology, pediatrics, and hospital sales is well known and we are certain that they will successfully bring this very useful new product to the market. There probably isn’t a better positioned company to get this in front of mothers, nurses and doctors who want to prevent unpleasant, painful experiences for their young children in the doctors office or hospital.”

Bullboard Posts